Drug Profile
Garivulimab - BeiGene
Alternative Names: BGB-A333Latest Information Update: 18 May 2021
Price :
$50
*
At a glance
- Originator BeiGene
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 06 May 2021 BeiGene terminates a phase I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia, New Zealand, Spain (IV) (NCT03379259)
- 06 May 2021 BeiGene terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia, New Zealand, Spain (IV) (NCT03379259)
- 26 Mar 2021 Phase I/II trial is still ongoing for Solid tumours in Australia, Spain and New Zealand (NCT03379259)